Zobrazeno 11 - 20
of 51
pro vyhledávání: '"35"'
Autor:
Tamas Hickish, E. A. Perez, Linda T. Vahdat, Ahmad Awada, David Cameron, Neil L. Spector, David A. Proia, Henry L. Gomez, Angel Rodriguez, John K. Erban, V. Vukovic, I Yalcin, Luis Fein, Anthony Kong, S Mansoor, A Giovanne, R Bradley, Iman El-Hariry, Karen McAdam, J-L Canon, J. Cortes, Iain R. Macpherson, Mano
Publikováno v:
Cancer Research. 73:P2-16
Background: Hsp90 is a molecular chaperone protein required for the stabilization and activation of many proteins, referred to as Hsp90 ‘clients’, such as HER2, HIF1-a, EGFR, ER, PI3K, AKT, P53 and VEGFR. The drug candidate, ganetespib is a novel
Autor:
C-Y Shiau, Y-L Wang, C-H Tzeng, J-H Chiu, L-M Tseng, K-L King, Y-M Shyr, Y.-F. Tsai, M-H Hung, T-C Chao, C-Y Liu
Publikováno v:
Cancer Research. 72:P3-12
Purpose: Biological subtypes and age were well-known risk factors associated with the development of brain metastasis in breast cancer patients. However the impact of each biological subtype in different age group was less discussed. Patient and meth
Autor:
Seock-Ah Im, Kevin Norwood, Donna M. Graham, Hyun Cheol Chung, Esma Saada-Bouzid, Alan D. Smith, Juanita Lopez, Javier Garcia-Corbacho, Carlos Gomez-Roca, Eduardo Castanon, Eduardo Yanez, Federico Longo Muñoz, Corina E. Dutcus, Razi Ghori
Publikováno v:
Cancer Research. 81:PS12-07
Background: Triple-negative breast cancer (TNBC) is associated with poor survival outcomes and treatment options are limited. These tumors lack therapeutic targets and become rapidly resistant to chemotherapy. The anti–PD-1 antibody pembrolizumab s
Autor:
Marine Martel, Ronwyn van Eeden, Jérôme Galon, B Mlecnik, Aurelie Fugon, Jacqui Barnard-Tidy, Carol Benn, Ronald Anderson, Teresa Smit, Bernardo Leon Rapoport, Simon Nayler
Publikováno v:
Cancer Research. 80:P1-10
Background: The presence of high levels of tumor infiltrating lymphocytes (TIL’s) has been associated with better prognosis in early triple-negative breast cancer (TNBC). The Immunoscore is a prognostic tool, which categorizes the densities of CD3
Autor:
Borhane Annabi, Cyndia Charfi, Jean-Christophe Currie, Alain Zgheib, Alain Larocque, Richard Béliveau, Christian Marsolais, Michel Demeule
Publikováno v:
Cancer Research. 80:P3-10
Background: Triple-negative breast cancer (TNBC) still lacks defined molecular biomarkers. Thus, targeting of specific gene/protein molecular signature of tumors emerged among the best anticancer strategies. Recently, increased expression of the cell
Autor:
Florian Bochen, Matthias Wagner, Mariz Kasoha, Barbara Linxweiler, Erich-Franz Solomayer, Merle Doerk, Maximilian Linxweiler, Z Takacs, MP Radosa, Julia Caroline Radosa, Rainer M. Bohle
Publikováno v:
Cancer Research. 80:P1-10
Background Chromosome 3q26 amplifications have been shown to represent a frequent alteration in various cancer entities including breast cancer. SEC62 - a 3q26 encoded gene - was identified as a potential oncogene and tumor-driver-gene for the pathog
Autor:
Carol Benn, Simon Nayler, Ronwyn van Eeden, Teresa Smit, Jacqui Barnard-Tidy, Bernardo Leon Rapoport
Publikováno v:
Cancer Research. 80:P2-16
Aim of study: The aim of this retrospective project is to evaluate the treatment outcomes including pathological complete response (pCR), time to progression and overall survival in patients (pts) treated with taxane, and/or anthracycline/alkylating
Publikováno v:
Cancer Research. 80:P6-08
Background: The National Comprehensive Cancer Network (NCCN) guidelines provide recommendations for which patients diagnosed with breast or ovarian cancer should have a referral for genetic evaluation. However, in a community setting without access t
Autor:
Wahl, Corey Speers, Kari Wilder-Romans, Daniel E. Spratt, Shyam Nyati, Eric Olsen, James M. Rae, Lori J. Pierce, Joel R. Eisner, Daniel F. Hayes, B. Chandler, Leah Moubadder, Felix Y. Feng
Publikováno v:
Cancer Research. 78:P1-09
Background: Increased rates of locoregional recurrence (LR) have been observed in TNBC despite chemotherapy and radiation (RT). A novel radiosensitizer screen nominated the AR as a promising target for treatment of radioresistant breast cancer, inclu
Autor:
J-U Blohmer, T Karn, Elmar Stickeler, Andreas Schneeweiss, C Denkert, V Müller, F Marmé, Anja Mueller, M. van Mackelenbergh, S. Loibl, Katharina Biehl, J Huober, Barbara Seliger, Michael Untch, PA Fasching, Karsten Weber, C. Jackisch, Claus Hanusch, Christian Schem, Chiara Massa
Publikováno v:
Cancer Research. 79:P4-06
Background: The GeparNuevo trial is a randomized, double-blind, multi-center phase II trial of neoadjuvant therapy in patients with early-stage triple negative breast cancer (TNBC) investigating the role of durvalumab, an anti-PD-L1 antibody, which b